DDX53: A Potential Drug Target and Biomarker (G168400)

Target Name: DDX53

NCBI ID: G168400

DDX53

DDX53: A Potential Drug Target and Biomarker

DDX53 is a gene that encodes a protein known as doublecortin (DCP), which is a zinc-dependent enzyme involved in the synthesis of adenosine, a key signaling molecule in the body. The discovery of DDX53 and its potential functions as a drug target and biomarker has significant implications for the development of new treatments for various diseases. In this article, we will explore the biology of DDX53, its potential as a drug target, and its potential as a biomarker for disease diagnosis and monitoring.

The Biology of DDX53

DDX53 is a gene that encodes a protein with 214 amino acid residues. The protein has a molecular weight of 24.9 kDa and a calculated pI of 9.95. It is expressed in various tissues and cells in the body, including the brain, heart, and pancreas. The protein is involved in the synthesis of adenosine, which is a key signaling molecule that plays a crucial role in various physiological processes in the body.

Adenosine is a small molecule that is synthesized from a template protein called adenosine monophosphate (AMP), which is generated from the DNA template that includes the sequence encoding adenosine. The DNA template is derived from the doublecortin gene, which encodes the protein known as doublecortin (DCP). The doublecortin gene is a member of the superfamily of RNA-protein hybrids, which are characterized by the presence of a transmembrane protein that is derived from a cytoskeletal protein and a protein that is derived from a ribonucleoprotein complex.

Doublecortin (DCP) is a zinc-dependent enzyme that is involved in the synthesis of adenosine fromAMP. Adenosine is a small molecule that plays a crucial role in various physiological processes in the body, including modulating inflammation, influencing pain perception, and regulating sleep-wake cycles. The activity of adenosine is regulated by various enzymes, including the doublecortin enzyme.

The Potential as a Drug Target

The discovery of DDX53 and its function as a protein involved in the synthesis of adenosine has significant implications for the development of new treatments for various diseases. One of the potential strategies for targeting DDX53 is to inhibit its activity, which would result in reduced levels of adenosine in the body. This would have a therapeutic effect on diseases that are characterized by inflammation, pain, or sleep disorders.

For example, diseases such as cancer, autoimmune disorders, and neurodegenerative diseases are characterized by inflammation and pain. In these diseases, the production of adenosine is often increased, which can contribute to the development and progression of the disease. Therefore, inhibiting the activity of DDX53 could be a promising strategy for treating these diseases.

Doublecortin (DCP) is also a potential drug target for diseases that are characterized by sleep disorders. Sleep disorders have been associated with various diseases, including cancer, neurodegenerative diseases, and sleep apnea. The production of adenosine is often increased in individuals with sleep disorders, which can contribute to the development and progression of these diseases. Therefore, inhibiting the activity of DDX53 could be a promising strategy for treating sleep disorders.

The Potential as a Biomarker

DDX53 may also be used as a biomarker for disease diagnosis and monitoring. The production of adenosine is a well-established biomarker for various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. Therefore, the levels of adenosine in the body can be used as a indicator of the presence of these diseases.

In addition to its use as a drug target, DDX53 may also be used as a biomarker for disease diagnosis and monitoring. The levels of adenosine in the body can be used to

Protein Name: DEAD-box Helicase 53

The "DDX53 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DDX53 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets